Skip to main content
    C

    Citius Pharmaceuticals Inc (CTXR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.53
    -0.01 (-1.40%)

    Market Cap: $14.69M

    Last updated: Nov 17, 2026 at 11:00 AM ET

    Citius Pharmaceuticals Inc (CTXR) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Citius Pharmaceuticals (CTXR) to earn -$1.44 per share in the fiscal year ending Sep 30, 2027, on revenue of $20.52M. Over the last 30 days, 0 estimates for the fiscal year ending Sep 30, 2027 were revised up and 1 down. For the quarter ending Dec 31, 2026, the EPS consensus is -$0.38.

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    Fiscal year ending Sep 30, 2027
    -$1.44
    EPS consensus, revenue $20.52M
    Next report
    Dec 21, 2026
    Estimated
    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Sep 30, 2027-$1.44-$1.44 to -$1.441$20.52M$20.52M to $20.52M1

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.38-$0.38 to -$0.381$4.40M$4.40M to $4.40M1

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 0 upward and 1 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Sep 30, 202701
    Quarter ending Dec 31, 202600

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Sep 30, 2027 has turned from a profit of $0.99 to a loss.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Sep 30, 2027-$1.44-$0.81-$0.81-$0.81$0.99N/A

    Frequently Asked Questions About CTXR

    What is the CTXR stock forecast?

    Consensus analyst estimates put Citius Pharmaceuticals's EPS at -$1.44 for the fiscal year ending Sep 30, 2027, on revenue of $20.52M.

    What EPS do analysts expect from CTXR next year?

    For the fiscal year ending Sep 30, 2027, the consensus EPS estimate is -$1.44, with estimates from -$1.44 to -$1.44 from 1 analyst.

    What revenue do analysts expect from Citius Pharmaceuticals next year?

    For the fiscal year ending Sep 30, 2027, the consensus revenue estimate is $20.52M, with estimates from $20.52M to $20.52M.

    How many analysts cover CTXR?

    1 analyst estimates EPS for Citius Pharmaceuticals for the fiscal year ending Sep 30, 2027.